| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Ethyl heptadecanoate does not have a defined primary pharmacological target as it is primarily a chemical reagent and biochemical research tool. As a fatty acid ester, the compound may interact with lipid membranes and lipid-binding proteins. In biochemical research, it may be used as a standard for lipid analysis, as a substrate for esterases and lipases, or as a model compound for studying fatty acid metabolism. Its role in chemical communication systems of various species suggests that it may interact with olfactory receptors or other chemosensory proteins. However, specific pharmacological targets have not been identified for this compound.
|
|---|---|
| ln Vitro |
In vitro activity of ethyl heptadecanoate as a standalone compound is not typically evaluated in pharmacological contexts, as it is primarily a chemical reagent and analytical standard. In biochemical research, the compound may be used as a substrate for esterase or lipase activity assays, where hydrolysis of the ester bond releases heptadecanoic acid and ethanol, which can be quantified by chromatographic methods. The compound may also be used as a reference standard in lipid analysis by GC-MS or other analytical techniques. Its role in chemical communication suggests potential activity in olfaction-related assays.
|
| ln Vivo |
In vivo activity data for ethyl heptadecanoate are not well documented in the pharmacological literature. The compound is primarily utilized as a chemical reagent and analytical standard rather than as a therapeutic agent. Its presence in pheromone or chemical communication systems of various species suggests that it may have ecological or behavioral functions, but pharmacological studies in mammals are limited. The compound is a fatty acid ester that would be expected to be hydrolyzed and metabolized like other dietary lipids if ingested.
|
| Enzyme Assay |
In vitro enzyme assays using ethyl heptadecanoate typically involve esterase or lipase activity measurements. A typical protocol involves incubating the compound with purified esterases, lipases, or tissue homogenates in appropriate buffer systems (e.g., Tris-HCl, pH 7.4–8.0) at 37°C for various time periods. The hydrolysis reaction produces heptadecanoic acid and ethanol, which can be quantified by GC-MS, HPLC, or other chromatographic methods. Enzyme activity is calculated based on the rate of substrate hydrolysis. Controls include reactions without enzyme and with heat-inactivated enzyme. The compound's limited water solubility requires the use of organic solvents or detergents in the assay.
|
| Cell Assay |
Cell-based in vitro experiments using ethyl heptadecanoate are not typically performed in pharmacological contexts, as the compound is a chemical reagent and analytical standard. When used in cell biology research, the compound might be tested for effects on lipid metabolism or membrane properties. Standard cell culture protocols would involve seeding cells in appropriate media at 37°C in a 5% CO₂ atmosphere, treating with the compound at various concentrations (with appropriate solubilization), and assessing cellular responses such as lipid accumulation, metabolic changes, or cytotoxicity using standard assays. The compound's limited water solubility should be considered in experimental design.
|
| Animal Protocol |
In vivo animal studies for ethyl heptadecanoate are not commonly performed in pharmacological contexts, as the compound is primarily a chemical reagent and analytical standard. For toxicological or metabolic studies, animals might be administered the compound via oral gavage at various dose levels, with assessment of metabolic parameters, lipid profiles, and general toxicity. As a fatty acid ester, the compound would be expected to be hydrolyzed and metabolized through fatty acid oxidation pathways. All animal studies must be conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ethyl heptadecanoate have not been extensively characterized. As a fatty acid ester with molecular weight 298.51 g/mol, the compound would be highly lipophilic with very low aqueous solubility. If ingested, the compound would be hydrolyzed by esterases in the gastrointestinal tract or liver, releasing heptadecanoic acid and ethanol. Heptadecanoic acid would be absorbed and metabolized through fatty acid oxidation pathways. The compound's high lipophilicity suggests extensive distribution to adipose tissue. However, detailed pharmacokinetic studies are limited, as the compound is primarily used as a research chemical rather than a pharmaceutical.
|
| Toxicity/Toxicokinetics |
Toxicological data for ethyl heptadecanoate are limited, as the compound is handled as a research chemical in laboratory environments. As a fatty acid ester, it is expected to have low acute toxicity. Standard safety precautions should be followed, including the use of appropriate personal protective equipment such as gloves, goggles, and lab coats. The compound may cause irritation to skin, eyes, and respiratory tract upon exposure. Inhalation of dust or vapor should be avoided, and adequate ventilation should be ensured. In case of contact, affected areas should be rinsed with plenty of water. The compound should be stored in a cool, dark place at <15°C, away from strong oxidizing agents. Comprehensive toxicological studies have not been reported.
|
| Additional Infomation |
It has been reported that horse chestnut (Aesculus indica) contains ethyl heptadecanate, and relevant data is available for reference.
Ethyl heptadecanoate is a chemical research tool and analytical standard rather than an approved pharmaceutical drug. Its primary applications are in biochemical research as a reference standard for lipid analysis and as a reagent for studying esterase and lipase activity. The compound is also utilized by various species in chemical communication systems, suggesting ecological and behavioral research applications. As a fatty acid ester, it may be used in studies of lipid metabolism, fatty acid oxidation, and lipid biochemistry. No clinical trials or regulatory approvals have been documented for this compound as a therapeutic agent. The compound is commercially available as a research-grade chemical with purity >97.0%, supplied for laboratory research. |
| Molecular Formula |
C19H38O2
|
|---|---|
| Molecular Weight |
298.50
|
| Exact Mass |
298.287
|
| CAS # |
14010-23-2
|
| PubChem CID |
26397
|
| Appearance |
<28°C Powder,>28°C Liquid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
337.7±5.0 °C at 760 mmHg
|
| Melting Point |
28°C
|
| Flash Point |
155.2±7.5 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.444
|
| LogP |
8.68
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
21
|
| Complexity |
214
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])C([H])([H])[H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
KNXMUFRWYNVISA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H38O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19(20)21-4-2/h3-18H2,1-2H3
|
| Chemical Name |
ethyl heptadecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (335.01 mM)
DMSO: 6.06 mg/mL (20.30 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3501 mL | 16.7504 mL | 33.5008 mL | |
| 5 mM | 0.6700 mL | 3.3501 mL | 6.7002 mL | |
| 10 mM | 0.3350 mL | 1.6750 mL | 3.3501 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
